UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Author Correction: Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors

NPJ systems biology and applications, 2024-08, Vol.10 (1), p.83-1, Article 83

2024

Volltextzugriff (PDF)

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

Nature communications, 2019-05, Vol.10 (1), p.1-22, Article 2030

2019

Volltextzugriff (PDF)

620 Multimodal real world data reveals immunogenomic drivers of acquired and primary resistance to immune checkpoint blockade

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A706-A707

2023

Volltextzugriff (PDF)

A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook

Science signaling, 2011, Vol.4 (170), p.er2

2011

Volltextzugriff (PDF)

Abstract B076: A DREAM-world of approaches for predicting combination synergies in cancer

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B076-B076

2018

Volltextzugriff (PDF)

Abstract 4171: Integrating pan-molecular data sets by bimodality to nominate synthetic lethal gene pairs and biomarkers of drug response

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4171-4171

2014

Volltextzugriff (PDF)

Abstract 3886: A large cancer pharmacogenomics combination screen powering crowd-sourced advancement of computational drug synergy predictions

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3886-3886

2018

Volltextzugriff (PDF)

Abstract 5724: Homologous recombination repair gene mutations for DNA repair and immune oncology drug combinations

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5724-5724

2018

Volltextzugriff (PDF)

Abstract B51: Tumor genetic shift post standard of care therapy

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B51-B51

2015

Volltextzugriff (PDF)

Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests

The Journal of molecular diagnostics : JMD, 2023-03, Vol.25 (3), p.143-155

2023

Volltextzugriff (PDF)

Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

Nature communications, 2024-06, Vol.15 (1), p.4871-21

2024

Volltextzugriff (PDF)

Abstract 225: Integration of patient-derived tumor organoids and patient clinical multimodal data to investigate the role of organoids in predicting treatment response

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.225-225

2024

Volltextzugriff (PDF)

Abstract A209: Predicting genetic drivers of MEK dependency with gene expression

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.A209-A209

2013

Volltextzugriff (PDF)

Abstract 6217: TP53 loss with whole genome doubling mediates heterogeneous intra-patient therapy response in EGFR-driven lung adenocarcinoma: A TRACERx study

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.6217-6217

2022

Volltextzugriff (PDF)

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF V600E amplification whereas KRAS G13D amplification promotes EMT-chemoresistance

Nature communications, 2019-05, Vol.10 (1), p.2030

2019

Volltextzugriff (PDF)

Abstract A13: Characterization of CRC primary explant models in comparison to standard human tumor cell-line-derived CRC xenografts

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A13-A13

2011

Volltextzugriff (PDF)

Abstract C2: Selection for combinational studies through biomarker stratification in colorectal patient-derived explant models

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.C2-C2

2011

Volltextzugriff (PDF)

Abstract 3497: Identifying pre-clinical predictive biomarkers for the PARP inhibitor olaparib

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.3497-3497

2010

Volltextzugriff (PDF)

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2 -mutant mammary tumours

Oncotarget, 2019-04, Vol.10 (27), p.2586-2606

2019

Volltextzugriff (PDF)

Correlation of PTEN loss and PI3K/AKT/mTOR pathway upregulation with malignant peripheral nerve sheath tumor (MPNST) development and outcome

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.10555-10555

2013

Volltextzugriff (PDF)

Ac, La, and Ce radioimpurities in 225 Ac produced in 40–200 MeV proton irradiations of thorium

Radiochimica acta, 2014-07, Vol.102 (7), p.569-581

2014

Volltextzugriff (PDF)

Genome-wide transcriptome analyses reveals p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumors

The Journal of pathology, 2010-01, Vol.220 (1), p.58-70

2010

Volltextzugriff (PDF)

Nietzsche’s Musical Conception of Time

Nietzsche on Time and History, 2008

Dries, Manuel

2008

Volltextzugriff (PDF)

Nietzsche’s Musical Conception of Time

Nietzsche on Time and History, 2008

Dries, Manuel

2008

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(22)
Buchkapitel
(2)

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Author Correction: Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

620 Multimodal real world data reveals immunogenomic drivers of acquired and primary resistance to immune checkpoint blockade

A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook

Abstract B076: A DREAM-world of approaches for predicting combination synergies in cancer

Abstract 4171: Integrating pan-molecular data sets by bimodality to nominate synthetic lethal gene pairs and biomarkers of drug response

Abstract 3886: A large cancer pharmacogenomics combination screen powering crowd-sourced advancement of computational drug synergy predictions

Abstract 5724: Homologous recombination repair gene mutations for DNA repair and immune oncology drug combinations

Abstract B51: Tumor genetic shift post standard of care therapy

Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests

Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

Abstract 225: Integration of patient-derived tumor organoids and patient clinical multimodal data to investigate the role of organoids in predicting treatment response

Abstract A209: Predicting genetic drivers of MEK dependency with gene expression

Abstract 6217: TP53 loss with whole genome doubling mediates heterogeneous intra-patient therapy response in EGFR-driven lung adenocarcinoma: A TRACERx study

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF V600E amplification whereas KRAS G13D amplification promotes EMT-chemoresistance

Abstract A13: Characterization of CRC primary explant models in comparison to standard human tumor cell-line-derived CRC xenografts

Abstract C2: Selection for combinational studies through biomarker stratification in colorectal patient-derived explant models

Abstract 3497: Identifying pre-clinical predictive biomarkers for the PARP inhibitor olaparib

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2 -mutant mammary tumours

Correlation of PTEN loss and PI3K/AKT/mTOR pathway upregulation with malignant peripheral nerve sheath tumor (MPNST) development and outcome

Ac, La, and Ce radioimpurities in 225 Ac produced in 40–200 MeV proton irradiations of thorium

Genome-wide transcriptome analyses reveals p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumors

Nietzsche’s Musical Conception of Time

Nietzsche’s Musical Conception of Time

Aktive Filter

Suchergebnisse filtern